they can be delayed with improved care, especially care early in diabetes progression,
which brings me to my third reason why new treatments are needed. Compliance or
adherence to taking medicine is really too low. While not many payers will say so
publicly, they indicate privately that adherence to diabetes medications is about 50% and
that’s on a really good day. This suggests that the armamentarium of diabetes
medications could possibly benefit from the addition of better, more tolerable therapies.
Notably, today there are no disease modifying alternatives for diabetes available.
Perhaps these can be developed one day. That’s truly a patient dream. For that to
happen, industry and investors must believe in a reasonable regulatory environment. If
they don’t we all will lose.
that same time period, the cost of diabetes complications doubled from under 20
billion to more than 40 billion. This is in five years. The expectations are that spending
on complications will increase to 53 billion in 2012 and 75 billion in 2020 if current
obesity trends continue. That’s new data from The Lewin Group who made all of the
data for the ADA publications on the cost of diabetes in America. Those came out earlier
answer is undoubtedly a combination of factors, but we believe from many surveys with
patients and doctors that it could largely be because current diabetes medications are not
broadly tolerable. The most widely used diabetes medication today, for example,
Metformin caused GI problems in 40% of patients who took it the international multi-
center randomized double-blinded placebo-controlled 44,000 patient DREAM trial. That
was reported in 2006.
As everyone here knows, many of these complications are preventable or
Why are A1cs so low? Why is diabetes management so challenging? The
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com